CL2020001546A1 - Compuestos de 4-azaindol. - Google Patents
Compuestos de 4-azaindol.Info
- Publication number
- CL2020001546A1 CL2020001546A1 CL2020001546A CL2020001546A CL2020001546A1 CL 2020001546 A1 CL2020001546 A1 CL 2020001546A1 CL 2020001546 A CL2020001546 A CL 2020001546A CL 2020001546 A CL2020001546 A CL 2020001546A CL 2020001546 A1 CL2020001546 A1 CL 2020001546A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- azaindole compounds
- azaindole
- toll
- inhibitors
- Prior art date
Links
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical class C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 102000002689 Toll-like receptor Human genes 0.000 abstract 1
- 108020000411 Toll-like receptor Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen los compuestos de Fórmula (I), N-óxidos, o sus sales, donde G, A, R1, R5, y n se definen en la presente. También se describen métodos de uso de tales compuestos como inhibidores de señalización a través del receptor tipo Toll 7, o 8, o 9, y composiciones farmacéuticas que comprenden tales. Estos compuestos son útiles para tratar enfermedades inflamatorias y autoinmunes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599875P | 2017-12-18 | 2017-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001546A1 true CL2020001546A1 (es) | 2020-10-23 |
Family
ID=65003548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001546A CL2020001546A1 (es) | 2017-12-18 | 2020-06-10 | Compuestos de 4-azaindol. |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US10544143B2 (es) |
| EP (1) | EP3728252B1 (es) |
| JP (1) | JP7289301B2 (es) |
| KR (1) | KR102720550B1 (es) |
| CN (1) | CN111819176B (es) |
| AR (1) | AR113959A1 (es) |
| AU (1) | AU2018388464B2 (es) |
| BR (1) | BR112020011771A2 (es) |
| CA (1) | CA3085817A1 (es) |
| CL (1) | CL2020001546A1 (es) |
| DK (1) | DK3728252T3 (es) |
| EA (1) | EA202091484A1 (es) |
| ES (1) | ES2960411T3 (es) |
| FI (1) | FI3728252T3 (es) |
| HR (1) | HRP20231244T1 (es) |
| HU (1) | HUE064473T2 (es) |
| IL (1) | IL275344B2 (es) |
| LT (1) | LT3728252T (es) |
| MX (1) | MX2020006168A (es) |
| PE (1) | PE20210129A1 (es) |
| PL (1) | PL3728252T3 (es) |
| PT (1) | PT3728252T (es) |
| RS (1) | RS64728B1 (es) |
| SG (1) | SG11202005628RA (es) |
| SI (1) | SI3728252T1 (es) |
| SM (1) | SMT202300342T1 (es) |
| TW (1) | TWI689510B (es) |
| WO (1) | WO2019125977A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| JP7289301B2 (ja) * | 2017-12-18 | 2023-06-09 | ブリストル－マイヤーズ スクイブ カンパニー | ４－アザインドール化合物 |
| SG11202005694RA (en) * | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Amino indole compounds useful as tlr inhibitors |
| KR102730859B1 (ko) * | 2017-12-20 | 2024-11-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 및 헤테로아릴 치환된 인돌 화합물 |
| CA3085937A1 (en) * | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Diazaindole compounds |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| WO2019233941A1 (en) | 2018-06-05 | 2019-12-12 | F. Hoffmann-La Roche Ag | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease |
| US11713327B2 (en) | 2018-06-12 | 2023-08-01 | Hoffmann-La Roche Inc. | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| JP7366994B2 (ja) | 2018-07-23 | 2023-10-23 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患治療用の新規ピペラジン化合物 |
| JP7233809B2 (ja) | 2018-09-04 | 2023-03-07 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのベンゾチアゾール化合物 |
| US12252484B2 (en) | 2018-09-06 | 2025-03-18 | Hoffmann-La Roche Inc. | Pyrazolopyridine compounds for the treatment of autoimmune disease |
| WO2020048595A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| WO2021067326A1 (en) * | 2019-10-01 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| ES2965164T3 (es) | 2019-10-04 | 2024-04-11 | Bristol Myers Squibb Co | Compuestos de carbazol sustituidos |
| EP4051387B1 (en) | 2019-10-31 | 2025-02-19 | F. Hoffmann-La Roche AG | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| EP4051388A1 (en) * | 2019-11-01 | 2022-09-07 | Bristol-Myers Squibb Company | Substituted pyrazole compounds as toll receptor inhibitors |
| US12486273B2 (en) | 2019-11-19 | 2025-12-02 | Hoffmann-La Roche Inc. | Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| CN114728988B (zh) | 2019-11-20 | 2024-12-10 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的螺(异苯并呋喃氮杂环丁烷)化合物 |
| MX2023001883A (es) * | 2020-08-19 | 2023-03-10 | Bristol Myers Squibb Co | Compuestos heteroarilicos sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9). |
| US12486267B2 (en) | 2020-08-19 | 2025-12-02 | Bristol-Myers Squibb Company | Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis |
| KR20230053645A (ko) | 2020-08-19 | 2023-04-21 | 브리스톨-마이어스 스큅 컴퍼니 | 섬유증의 치료를 위한 tlr9 억제제로서의 1h-벤조[d]이미다졸 유도체 |
| AU2021328577A1 (en) | 2020-08-19 | 2023-03-23 | Bristol-Myers Squibb Company | 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis |
| CN116490506B (zh) * | 2020-11-26 | 2024-12-13 | 江苏恒瑞医药股份有限公司 | 稠合三环化合物、其制备方法及其在医药上的应用 |
| CN116783202A (zh) * | 2021-02-09 | 2023-09-19 | 吉利德科学公司 | 噻吩并吡咯化合物 |
| TWI861488B (zh) | 2021-04-16 | 2024-11-11 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| US12070455B2 (en) | 2021-09-10 | 2024-08-27 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| CN114591339B (zh) * | 2022-05-10 | 2022-08-02 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
| TWI899933B (zh) | 2023-04-06 | 2025-10-01 | 美商輝瑞大藥廠 | 經取代吲唑丙酸衍生化合物及其用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2306870A1 (en) | 1997-10-20 | 1999-04-29 | David Michael Goldstein | Bicyclic kinase inhibitors |
| EE200100323A (et) | 1998-12-18 | 2002-08-15 | Axys Pharmaceuticals, Inc. | (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena |
| JP2007524615A (ja) | 2003-06-20 | 2007-08-30 | コーリー ファーマシューティカル ゲーエムベーハー | 低分子トール様レセプター（ｔｌｒ）アンタゴニスト |
| WO2005111042A1 (en) | 2004-05-03 | 2005-11-24 | Janssen Pharmaceutica N.V. | Novel indole derivatives as selective androgen receptor modulators (sarms) |
| US20060235037A1 (en) | 2005-04-15 | 2006-10-19 | Purandare Ashok V | Heterocyclic inhibitors of protein arginine methyl transferases |
| JP2009532501A (ja) | 2006-04-04 | 2009-09-10 | ミリアド ジェネティクス， インコーポレイテッド | 疾患および障害のための化合物 |
| DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| ATE495743T1 (de) | 2006-12-01 | 2011-02-15 | Galapagos Nv | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
| GB0708141D0 (en) | 2007-04-26 | 2007-06-06 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
| CL2009000904A1 (es) * | 2008-04-21 | 2010-04-30 | Shionogi & Co | Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende. |
| AU2009268611B2 (en) * | 2008-07-08 | 2015-04-09 | Intellikine, Llc | Kinase inhibitors and methods of use |
| EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| US8785489B2 (en) | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
| AU2009333559B2 (en) * | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| TR201809739T4 (tr) | 2009-07-16 | 2018-07-23 | Mallinckrodt Llc | Toll benzeri reseptör 9 antagonistleri olarak (+)-morfinanlar ve bunların terapötik amaçlı kullanımları. |
| US9241991B2 (en) | 2010-10-21 | 2016-01-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritus and related skin conditions |
| CA2824779C (en) | 2011-01-12 | 2020-01-14 | Array Biopharma, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| ES2620605T3 (es) | 2011-01-12 | 2017-06-29 | Ventirx Pharmaceuticals, Inc. | Benzoazepinas sustituidas como moduladores de receptores tipo Toll |
| WO2012167053A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| RU2606114C2 (ru) | 2011-06-01 | 2017-01-10 | Джейнус Байотерапьютикс, Инк. | Новые модуляторы иммунной системы |
| AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
| ES2555167T3 (es) | 2011-07-15 | 2015-12-29 | Janssen Pharmaceuticals, Inc. | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa |
| JP2013075834A (ja) * | 2011-09-29 | 2013-04-25 | Kowa Co | Ｔｌｒ９阻害活性を有するピラゾロピリミジン−７−アミン誘導体 |
| CA2850932A1 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| EP2850067B1 (en) | 2012-05-18 | 2017-08-16 | Sumitomo Dainippon Pharma Co., Ltd. | Carboxylic acid compounds |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| EP2738172A1 (en) * | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| TWI624467B (zh) | 2013-10-14 | 2018-05-21 | 衛材Ｒ＆Ｄ企管股份有限公司 | 選擇性經取代之喹啉化合物 |
| CA2933466A1 (en) * | 2013-12-13 | 2015-06-18 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| MX386981B (es) * | 2014-08-15 | 2025-03-19 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7). |
| WO2016029077A1 (en) | 2014-08-22 | 2016-02-25 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| AR103232A1 (es) * | 2014-12-22 | 2017-04-26 | Bristol Myers Squibb Co | ANTAGONISTAS DE TGFbR |
| MX391344B (es) | 2016-07-30 | 2025-03-21 | Bristol Myers Squibb Co | Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). |
| JP7028861B2 (ja) | 2016-09-09 | 2022-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | ピリジル置換のインドール化合物 |
| JP7289301B2 (ja) * | 2017-12-18 | 2023-06-09 | ブリストル－マイヤーズ スクイブ カンパニー | ４－アザインドール化合物 |
-
2018
- 2018-12-17 JP JP2020533676A patent/JP7289301B2/ja active Active
- 2018-12-17 PT PT188306484T patent/PT3728252T/pt unknown
- 2018-12-17 ES ES18830648T patent/ES2960411T3/es active Active
- 2018-12-17 RS RS20230961A patent/RS64728B1/sr unknown
- 2018-12-17 AR ARP180103685A patent/AR113959A1/es unknown
- 2018-12-17 MX MX2020006168A patent/MX2020006168A/es unknown
- 2018-12-17 KR KR1020207020519A patent/KR102720550B1/ko active Active
- 2018-12-17 US US16/222,145 patent/US10544143B2/en active Active
- 2018-12-17 WO PCT/US2018/065908 patent/WO2019125977A1/en not_active Ceased
- 2018-12-17 AU AU2018388464A patent/AU2018388464B2/en active Active
- 2018-12-17 EP EP18830648.4A patent/EP3728252B1/en active Active
- 2018-12-17 DK DK18830648.4T patent/DK3728252T3/da active
- 2018-12-17 PL PL18830648.4T patent/PL3728252T3/pl unknown
- 2018-12-17 HU HUE18830648A patent/HUE064473T2/hu unknown
- 2018-12-17 SG SG11202005628RA patent/SG11202005628RA/en unknown
- 2018-12-17 PE PE2020000741A patent/PE20210129A1/es unknown
- 2018-12-17 LT LTEPPCT/US2018/065908T patent/LT3728252T/lt unknown
- 2018-12-17 TW TW107145397A patent/TWI689510B/zh not_active IP Right Cessation
- 2018-12-17 HR HRP20231244TT patent/HRP20231244T1/hr unknown
- 2018-12-17 CA CA3085817A patent/CA3085817A1/en active Pending
- 2018-12-17 SI SI201830990T patent/SI3728252T1/sl unknown
- 2018-12-17 FI FIEP18830648.4T patent/FI3728252T3/fi active
- 2018-12-17 SM SM20230342T patent/SMT202300342T1/it unknown
- 2018-12-17 CN CN201880080921.XA patent/CN111819176B/zh active Active
- 2018-12-17 BR BR112020011771-4A patent/BR112020011771A2/pt unknown
- 2018-12-17 EA EA202091484A patent/EA202091484A1/ru unknown
-
2019
- 2019-11-26 US US16/695,303 patent/US10730877B2/en active Active
-
2020
- 2020-06-10 CL CL2020001546A patent/CL2020001546A1/es unknown
- 2020-06-14 IL IL275344A patent/IL275344B2/en unknown
- 2020-06-24 US US16/910,101 patent/US11053244B1/en active Active
-
2021
- 2021-04-30 US US17/245,595 patent/US11820768B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| UY37310A (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| EA202091508A1 (ru) | 6-азаиндольные соединения | |
| ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| MX390698B (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| EA202091480A1 (ru) | Аминоиндольные соединения, пригодные в качестве ингибиторов tlr | |
| DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| CL2017000712A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| CO2020015747A2 (es) | Analogos de rapamicina y usos de los mismos | |
| CR20160321A (es) | Modulares de tetrahidropiridopirazinas de gpr6 | |
| DOP2017000289A (es) | Moduladores de receptor nuclear | |
| CR20160374A (es) | Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina | |
| CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
| CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. | |
| CO2019004164A2 (es) | Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa | |
| CR20160084A (es) | Derivados de amida como agonistas del receptor del ácido lisofosfatídico | |
| UY35947A (es) | Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen | |
| CO2019004143A2 (es) | Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa | |
| ECSP16074482A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
| MX2019011517A (es) | Proceso para producir analogos de anillo de arilomicina. |